Clinical trial
AZD2171 to Treat Prostate Cancer
NCT00436956 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00436956 |
|---|---|
| Title | AZD2171 to Treat Prostate Cancer |
| Official title | A Phase II Study of AZD2171 in Metastatic Androgen Independent Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Magnetic Resonance Imaging (DCE-MRI), AZD2171, Prednisone |
| Enrollment | 59 |
| Start date | Oct 16, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Feb 5, 2014 |
| First posted | Feb 19, 2007 |
| Last update posted | Oct 9, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: